It has been shown that RAL has a potential therapeutic perspective in the moderation of obesity, dyslipidemia, and endothelial dysfunction thus on reducing the occurrence of atherosclerotic processes. This evidence concerns the gene RALA and obesity due to melanocortin 4 receptor deficiency.